Back to School: How biopharma can reboot drug development. Access exclusive analysis here

T-knife: creating TCR factories with transgenic mice

With €66M series A, T-knife to bring four TCR therapies into the clinic by 2022

Armed with a €66 million ($78.2 million) series A round, T-knife emerged from stealth Thursday with plans to bring four TCR therapies into clinical testing by 2022 using a transgenic mouse platform designed to generate human, high affinity TCRs.

The Berlin-based company spun out of the

Read the full 450 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers